BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. The company was founded in 1993 and is headquartered in Laval, Canada.
IPO Year: 2019
Exchange: NASDAQ
Website: bellushealth.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/19/2023 | Outperform → Sector Perform | RBC Capital Mkts | |
| 2/24/2022 | $14.00 → $16.00 | Buy | HC Wainwright & Co. |
| 12/13/2021 | $12.00 → $20.00 | Outperform | Evercore ISI Group |
| 12/7/2021 | $9.00 → $11.00 | Outperform | RBC Capital |
| 10/18/2021 | $8.00 → $9.00 | Outperform | RBC Capital |
| 9/14/2021 | $10.00 → $14.00 | Buy | HC Wainwright & Co. |
| 7/29/2021 | $9.00 | Buy | BTIG Research |
RBC Capital Mkts downgraded BELLUS Health from Outperform to Sector Perform
HC Wainwright & Co. reiterated coverage of BELLUS Health with a rating of Buy and set a new price target of $16.00 from $14.00 previously
Evercore ISI Group reiterated coverage of BELLUS Health with a rating of Outperform and set a new price target of $20.00 from $12.00 previously
RBC Capital reiterated coverage of BELLUS Health with a rating of Outperform and set a new price target of $11.00 from $9.00 previously
RBC Capital reiterated coverage of BELLUS Health with a rating of Outperform and set a new price target of $9.00 from $8.00 previously
HC Wainwright & Co. reiterated coverage of BELLUS Health with a rating of Buy and set a new price target of $14.00 from $10.00 previously
BTIG Research initiated coverage of BELLUS Health with a rating of Buy and set a new price target of $9.00
RBC Capital initiated coverage of BELLUS Health with a rating of Outperform and set a new price target of $8.00
15-12G - BELLUS Health Inc. (0001259942) (Filer)
S-8 POS - BELLUS Health Inc. (0001259942) (Filer)
S-8 POS - BELLUS Health Inc. (0001259942) (Filer)
6-K - BELLUS Health Inc. (0001259942) (Filer)
6-K - BELLUS Health Inc. (0001259942) (Filer)
6-K - BELLUS Health Inc. (0001259942) (Filer)
6-K - BELLUS Health Inc. (0001259942) (Filer)
6-K - BELLUS Health Inc. (0001259942) (Filer)
6-K - BELLUS Health Inc. (0001259942) (Filer)
6-K - BELLUS Health Inc. (0001259942) (Filer)
LONDON, June 28, 2023 /CNW/ - GSK plc (LSE: GSK) (NYSE:GSK) and BELLUS Health Inc. (TSX:BLU) NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC), by way of a plan of arrangement in accordance with Section 192 of the Canada Business Corporations Act (the "Arrangement"). The Arrangement was approved by BELLUS' shareholders on 16 June 2023. As previously announced, the acquisition of BELLUS includes camlipixant, a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with R
BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS" or the "Company") today announced the positive outcome of the BELLUS shareholders ("Shareholders") vote at this morning's special meeting of the Shareholders (the "Special Meeting") held in-person, approving the previously-announced statutory plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which 14934792 Canada Inc. (the "Purchaser"), a corporation existing under the laws of Canada and a wholly-owned subsidiary of GSK plc (NYSE:GSK, LSE: GSK))) ("GSK"), will acquire, for a purchase price of US$14.75 in cash per share, all of the issued and outstanding common shares of BELLUS (the
Special Meeting to be held on June 16, 2023 BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS" or the "Company") today announced that the Superior Court of Québec has issued an interim order authorizing, among other things, the holding of a special meeting (the "Special Meeting") of shareholders of BELLUS ("Shareholders") on June 16, 2023. At the Special Meeting, Shareholders will be asked to consider and, if deemed advisable, to adopt a special resolution (the "Arrangement Resolution") approving the previously-announced statutory plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which 14934792 Canada Inc. (the "Purchaser"), a co
- Announced agreement to be acquired by GSK for US$14.75 per share of common stock in cash representing an approximate total equity value of US$2.0 billion and a premium of approximately 103%; transaction expected to close in Q3 2023 – BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough ("RCC"), today reported its financial and operating results for the quarter ended March 31, 2023. "Our merger agreement with GSK underscores our corporate and clini
BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough ("RCC"), has announced the meeting and record dates for the special meeting of shareholders to be held in connection with the acquisition of the Company by GSK plc for US$2.0 billion pursuant to a plan of arrangement (the "Acquisition Meeting"). The Company will hold the Acquisition Meeting to consider the acquisition on June 16, 2023. The Company's Board of Directors has unanimously recommended that
Acquisition further strengthens specialty medicines and respiratory pipeline with camlipixant, a highly selective P2X3 antagonist and potential best-in-class treatment for refractory chronic cough Currently in phase III clinical development with anticipated regulatory approval and launch in 2026 Accretive to adjusted EPS from 2027 with significant sales potential through 2031 GSK plc (NYSE:GSK) and BELLUS Health Inc. (NASDAQ:BLU) today announced that they have entered into an agreement under which GSK will acquire BELLUS, a Canada-based, late-stage biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC) for US$14.75 per share
Once-daily Extended-Release formulation demonstrated equivalent bioavailability to twice-daily Immediate Release formulation Extended-Release formulation was well tolerated, with the safety profile consistent with previous camlipixant trials and no taste-related adverse events reported Additional data to be presented at a future medical conference BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough ("RCC"), today announced positive data from its
- Patient enrollment ongoing in the CALM Phase 3 program with topline data expected for CALM-1 in the second half of 2024 - - Ended year with US$337.1 million in cash, cash equivalents and short-term investments; cash runway extends to the second half of 2025 and through expected topline results of both CALM-1 and CALM-2 trials - BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough ("RCC"), today reported its financial and operating results for the ye
BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will participate in the Respiratory/Infections panel discussion at the Cowen 43rd Annual Health Care Conference, being held March 6 - 8, 2023 in Boston, MA. Respiratory/Infections Panel Discussion Details: Event: Cowen 43rd Annual Health Care Conference Date/Time: Wednesday, March 8th, 2023 at 10:30 a.m. ET Location: Boston, MA A webcast of the panel
BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, today announced that two abstracts describing the patient medical journey and the negative impact of RCC on quality of life will be presented at the upcoming American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, being held in San Antonio, Texas from February 24-27, 2023. Poster Presentation Details: Title: Burden of Cough in Refractory Chronic Cough Populations Enrolled in A Phase 2b Study of the P2X3 Antagonist BLU-5937 Dat
SC 13G - BELLUS Health Inc. (0001259942) (Subject)
SC 13G/A - BELLUS Health Inc. (0001259942) (Subject)
SC 13G - BELLUS Health Inc. (0001259942) (Subject)
SC 13G/A - BELLUS Health Inc. (0001259942) (Subject)
SC 13G/A - BELLUS Health Inc. (0001259942) (Subject)
SC 13G/A - BELLUS Health Inc. (0001259942) (Subject)
SC 13G/A - BELLUS Health Inc. (0001259942) (Subject)
SC 13G/A - BELLUS Health Inc. (0001259942) (Subject)
SC 13G - BELLUS Health Inc. (0001259942) (Subject)
SC 13G - BELLUS Health Inc. (0001259942) (Subject)
NEW YORK, Jan. 4, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics, today announced the appointment of serial entrepreneur Robert Forrester and venture capitalist Chau Khuong as independent board directors. "We are delighted to have Robert and Chau, two seasoned leaders with a wealth of insights and expertise, to join OnCusp's Board. Both are highly regarded and deeply connected in the biotech and investment community," said Dr. Bing Yuan, Chairman and CEO of OnCusp. "Each of these individuals brings unique skill sets to our Board and will be instrumental to advancing OnCusp through se
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced the appointment of William Mezzanotte, MD, MPH to its Board of Directors. Dr. Mezzanotte brings decades of vast development and commercial experience to the Board, including the development and approval of 30 products across multiple therapeutic areas. “Bill is a biopharmaceutical veteran with a proven drug development track record, including the approval of several drugs within the respiratory field,” c
LONDON, June 28, 2023 /CNW/ - GSK plc (LSE: GSK) (NYSE:GSK) and BELLUS Health Inc. (TSX:BLU) NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC), by way of a plan of arrangement in accordance with Section 192 of the Canada Business Corporations Act (the "Arrangement"). The Arrangement was approved by BELLUS' shareholders on 16 June 2023. As previously announced, the acquisition of BELLUS includes camlipixant, a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with R
Primary efficacy endpoint statistically significant with 34% placebo-adjusted reduction in 24-hour cough frequency observed at 50 mg and 200 mg BID doses (p ≤ 0.005) BLU-5937 was well-tolerated with a low rate of taste-related adverse events (≤6.5%); treatment emergent adverse event profile comparable to placebo Company also provides an update on its P2X3 pipeline and BLU-5937 Phase 2a trial for the treatment of chronic pruritus Company to host conference call and webcast at 8:00 a.m. ET BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC"